Elanco Animal Health (NYSE:ELAN) Shares Down 8.2% – What’s Next?

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) traded down 8.2% on Monday . The company traded as low as $21.86 and last traded at $21.72. 5,032,741 shares traded hands during trading, a decline of 1% from the average session volume of 5,100,093 shares. The stock had previously closed at $23.65.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Leerink Partners lifted their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. lifted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $28.20.

Elanco Animal Health Trading Down 8.4%

The stock has a fifty day moving average of $23.81 and a 200 day moving average of $23.35. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a market capitalization of $10.82 billion, a PE ratio of -43.34, a PEG ratio of 2.67 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same period in the previous year, the firm earned $0.37 EPS. The firm’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC increased its stake in Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the last quarter. Lazard Asset Management LLC increased its stake in Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC increased its stake in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares during the last quarter. Meeder Advisory Services Inc. increased its stake in Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares during the last quarter. Finally, Bessemer Group Inc. increased its stake in Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.